Trials / Terminated
TerminatedNCT02568683
Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)
A Phase 1b-2, Open-Label, Dose Escalation and Expansion Study Evaluating the Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to evaluate the safety of ENTO with VCR in participants with relapsed or refractory B-cell NHL.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Entospletinib | ENTO spray dried dispersion tablets administered orally twice daily while in a fasted state |
| DRUG | Vincristine | VCR administered intravenously |
Timeline
- Start date
- 2016-02-11
- Primary completion
- 2016-10-03
- Completion
- 2017-06-22
- First posted
- 2015-10-06
- Last updated
- 2019-04-17
- Results posted
- 2019-04-17
Locations
7 sites across 2 countries: United States, France
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02568683. Inclusion in this directory is not an endorsement.